Search
Anika Therapeutics Inc
ANIKAdd to Watchlist
14.420USD
+0.190+1.34%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
192.61MMarket Cap
LossP/E TTM
More Details of Anika Therapeutics Inc Company
Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Anika Therapeutics Inc Info
Ticker SymbolANIK
Company nameAnika Therapeutics Inc
IPO dateMay 16, 1985
CEOBlanchard (Cheryl Renee)
Number of employees288
Security typeOrdinary Share
Fiscal year-endMay 16
Address32 Wiggins Ave
CityBEDFORD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01730-2315
Phone17814579000
Websitehttps://anika.com/
Ticker SymbolANIK
IPO dateMay 16, 1985
CEOBlanchard (Cheryl Renee)
Company Executives of Anika Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Stephen D. (Steve) Griffin
Mr. Stephen D. (Steve) Griffin
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
90.25K
+10.05%
Dr. Glenn R. Larsen, Ph.D.
Dr. Glenn R. Larsen, Ph.D.
Independent Director
Independent Director
50.26K
--
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
42.57K
+6.40%
Mr. William R. (Bill) Jellison
Mr. William R. (Bill) Jellison
Independent Director
Independent Director
23.10K
--
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Independent Director
Independent Director
20.40K
--
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Susan L. N. Vogt
Ms. Susan L. N. Vogt
Independent Director
Independent Director
--
--
Mr. David B. Colleran, J.D.
Mr. David B. Colleran, J.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
--
--
Mr. John Bell (Jack) Henneman, III
Mr. John Bell (Jack) Henneman, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Stephen O. Richard
Mr. Stephen O. Richard
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Stephen D. (Steve) Griffin
Mr. Stephen D. (Steve) Griffin
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
90.25K
+10.05%
Dr. Glenn R. Larsen, Ph.D.
Dr. Glenn R. Larsen, Ph.D.
Independent Director
Independent Director
50.26K
--
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
42.57K
+6.40%
Mr. William R. (Bill) Jellison
Mr. William R. (Bill) Jellison
Independent Director
Independent Director
23.10K
--
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Independent Director
Independent Director
20.40K
--
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
FAQs
Who are the top five shareholders of Anika Therapeutics Inc?
The top five shareholders of Anika Therapeutics Inc are: Mr. Stephen D. (Steve) Griffin
How many institutions hold shares of Anika Therapeutics Inc (ANIK)?
As of 2026Q1, 264 institutions hold shares of Anika Therapeutics Inc, with a combined market value of approximately 12.85M, accounting for 96.55% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1611291.00.
What is the biggest source of revenue for Anika Therapeutics Inc?
In 2026Q1, the OEM Channel business generated the highest revenue for Anika Therapeutics Inc, amounting to 64.41M and accounting for 57.09% of total revenue.
